SHPH (Shuttle Pharmaceuticals Holdings) EV-to-FCF: -0.15 (As of Jun. 28, 2026)


SHPH Shuttle Pharmaceuticals Holdings Inc SHPH
24 GF Score
Price $3.98
! 1 Warning Sign
View Full Analysis

What is Shuttle Pharmaceuticals Holdings EV-to-FCF?

Shuttle Pharmaceuticals Holdings SHPH +6.35% 24 EV-to-FCF is -0.15 as of Jun. 28, 2026. GuruFocus rates SHPH with a GF Score™ of 24/100. The stock has 1 warning sign investors should review. Among 562 Drug Manufacturers companies, Shuttle Pharmaceuticals Holdings ranks worse than 177935.77% on this metric.

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Shuttle Pharmaceuticals Holdings's Enterprise Value is $1.45 Mil. Shuttle Pharmaceuticals Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-9.41 Mil. Therefore, Shuttle Pharmaceuticals Holdings's EV-to-FCF for today is -0.15.

The historical rank and industry rank for Shuttle Pharmaceuticals Holdings's EV-to-FCF or its related term are showing as below:

SHPH' s EV-to-FCF Range Over the Past 10 Years
Min: -0.15   Med: 0   Max: 0
Current: -0.15

SHPH's EV-to-FCF is ranked worse than
100% of 562 companies
in the Drug Manufacturers industry
Industry Median: 20.11 vs SHPH: -0.15

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-06-28), Shuttle Pharmaceuticals Holdings's stock price is $3.98. Shuttle Pharmaceuticals Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-60.622. Therefore, Shuttle Pharmaceuticals Holdings's PE Ratio (TTM) for today is At Loss.


Shuttle Pharmaceuticals Holdings  (NAS:SHPH) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Shuttle Pharmaceuticals Holdings's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.98/-60.622
=At Loss

Shuttle Pharmaceuticals Holdings's share price for today is $3.98.
Shuttle Pharmaceuticals Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-60.622.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Shuttle Pharmaceuticals Holdings EV-to-FCF Related Terms


Shuttle Pharmaceuticals Holdings EV-to-FCF Historical Data

* Premium members only.

The historical data trend for Shuttle Pharmaceuticals Holdings's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shuttle Pharmaceuticals Holdings EV-to-FCF Chart

Shuttle Pharmaceuticals Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EV-to-FCF
Get a 7-Day Free Trial 0.00 -7.42 -0.52 -0.37 -0.28

Shuttle Pharmaceuticals Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.01 -0.27 -0.28 -0.31

SHPH vs PRFX, CBIH, UPC: EV-to-FCF Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shuttle Pharmaceuticals Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shuttle Pharmaceuticals Holdings EV-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shuttle Pharmaceuticals Holdings's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Shuttle Pharmaceuticals Holdings's EV-to-FCF falls into.


SHPH
24GF Score
Shuttle Pharmaceuticals Holdings Inc SHPH
EV-to-FCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shuttle Pharmaceuticals Holdings EV-to-FCF Calculation

Shuttle Pharmaceuticals Holdings's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1.453/-9.408
=-0.15

Shuttle Pharmaceuticals Holdings's current Enterprise Value is $1.45 Mil.
Shuttle Pharmaceuticals Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-FCF →
What does a EV-to-FCF of -0.15 mean?
Shuttle Pharmaceuticals Holdings (SHPH) has a EV-to-FCF of -0.15 as of Jun. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shuttle Pharmaceuticals Holdings and its competitors. According to the industry distribution chart, Shuttle Pharmaceuticals Holdings ranks #999999 out of 562 companies in the Drug Manufacturers industry.
Is Shuttle Pharmaceuticals Holdings' EV-to-FCF too high?
Shuttle Pharmaceuticals Holdings' current EV-to-FCF is -0.15. Based on the distribution chart, Shuttle Pharmaceuticals Holdings ranks #999999 out of 562 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shuttle Pharmaceuticals Holdings has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Shuttle Pharmaceuticals Holdings' EV-to-FCF compare to PRFX and CBIH?
According to the Drug Manufacturers industry distribution chart, Shuttle Pharmaceuticals Holdings ranks #999999 out of 562 companies for EV-to-FCF. This places Shuttle Pharmaceuticals Holdings in the lower half of its industry. The industry median EV-to-FCF is 20.11. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.11, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shuttle Pharmaceuticals Holdings and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shuttle Pharmaceuticals Holdings's current EV-to-FCF is -0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shuttle Pharmaceuticals Holdings stock overvalued right now?
Shuttle Pharmaceuticals Holdings (SHPH) has a current EV-to-FCF of -0.15. The current EV-to-FCF is -0.15. Shuttle Pharmaceuticals Holdings' overall GF Score™ is 24/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Shuttle Pharmaceuticals Holdings (SHPH), the current EV-to-FCF is -0.15 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shuttle Pharmaceuticals Holdings Business Description

Address 401 Professional Drive, Suite 260, Gaithersburg, MD, USA, 20879
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.
24GF Score

Get the complete analysis for SHPH

EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.98
Price